Skip to content

A Study of the Efficacy of Subcutaneous Phosphatidylcholine and Deoxycholate Injections for Localized Fat Removal

A Randomized, Double-Blinded, Study of the Efficacy of Subcutaneous Phosphatidylcholine and Deoxycholate Injections for Localized Fat Removal

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00851747
Enrollment
18
Registered
2009-02-26
Start date
2009-02-28
Completion date
2009-10-31
Last updated
2018-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

The primary objective of this study is to determine the efficacy of phosphatidylcholine and deoxycholate subcutaneous injections for localized fat removal. Subcutaneous injections of the study drug will be efficacious in decreasing localized fat deposits due to the known fat necrosis effects on fat tissue after study drug tissue incubation.

Detailed description

This study is a randomized, double-blind study of 21 subjects. Participants in this study will be healthy, non-obese (BMI \<30) subjects over 25 with two localized, symmetrical, and contralateral areas of fat deposition on the abdomen or flanks and on the buttocks or thighs that have proven resistant to diet and exercise. Each participant will be randomized to one of three groups and will receive 4 series of injections two weeks apart. Multiple injections will be placed in the subdermal fat layer from 1-1.5 cm apart depending on the size of the treatment area. Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections. The study sites will include a symmetric, contralateral area of localized fat deposit on both the upper and lower torso. Clinical evaluations will be performed at each visit. Hematologic and ultrasonographic evaluations will be performed at baseline, at the 3rd treatment (Week 4), and at 6 month follow-up. Histologic evaluations will be performed on select individuals at baseline and at the 3rd treatment (Week 4) visit.

Interventions

DRUGPhosphatidylcholine Deoxycholate

Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections

DRUGSaline

Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections

Sponsors

The Cleveland Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

double-blind

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 25 and over * BMI of 18.5-29.99 * Two localized areas of fat deposition on the upper and lower torso that have failed on self-reported diet and exercise * The subject is in good health * The subject has the willingness and the ability to understand and provide informed consent

Exclusion criteria

* Under 25 years of age * Pregnancy or Lactation * BMI≥ 30 * Subjects with known eating disorders or a history of weight loss/gain of 5 pounds or more within the past 6 months * Subjects with hepatrophy, nephopathy, diabetes, hyperthyroidism, neoplasias, AIDS or other immuno-compromised illness, allergies to eggs or soy, poorly controlled hypertension, or autoimmune disease * Subjects currently taking blood thinners or who have had chemotherapy or radiation within the last 6 months * Subjects with an open, non-healing sore or infection near site of injection * Subjects with active eczema or psoriasis * Subjects who are unable to understand the protocol or to give informed consent * Subjects with mental illness

Design outcomes

Primary

MeasureTime frameDescription
Efficacy of Phosphatidylcholine and Deoxycholate Subcutaneous Injections for Localized Fat Removal.1 yearThe primary objective of this study is to determine the efficacy of phosphatidylcholine and deoxycholate subcutaneous injections for localized fat removal. Subcutaneous injections of the study drug will be efficacious in decreasing localized fat deposits

Countries

United States

Participant flow

Participants by arm

ArmCount
C Phosphatidylcholine Deoxycholate
Phosphatidylcholine Deoxycholate Injections
6
A Saline
Group A will serve as a control and will receive only injections of saline as a placebo.
6
B PhosphatidylcholineDeoxycholate/Saline
Group B will receive saline injections on one side of the body and receive PhosphatidylcholineDeoxycholate injections on the contralateral side.
6
Total18

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyPhysician Decision666

Baseline characteristics

CharacteristicTotalC Phosphatidylcholine DeoxycholateA SalineB PhosphatidylcholineDeoxycholate/Saline
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants0 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
0 / 60 / 60 / 6
serious
Total, serious adverse events
0 / 60 / 60 / 6

Outcome results

Primary

Efficacy of Phosphatidylcholine and Deoxycholate Subcutaneous Injections for Localized Fat Removal.

The primary objective of this study is to determine the efficacy of phosphatidylcholine and deoxycholate subcutaneous injections for localized fat removal. Subcutaneous injections of the study drug will be efficacious in decreasing localized fat deposits

Time frame: 1 year

Population: PI left institution and no data is available.

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026